Nhà máy Stada
Antihistamines & Antiallergics

Fexostad 180


Pack size:

Box of 1 blister x 10 film-coated tablets.


Each film-coated tablet contains fexofenadine hydrochloride 180 mg.



24 months from the date of manufacturing.

Store in a well-closed container, in a dry place. Do not store above 30oC.


  • Indications and Dosage & Administration
  • Contraindications
  • Adverse reactions
  • Precautions

  • Relief of symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older.
  • Treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older.
  • Orally taken before a meal.
  • Adults and children aged 12 years and over:
    180 mg (one tablet) once daily.
  • Children under 12 years old:
    Efficacy and safety of fexofenadine hydrochloride has not been studied in children under 12.

Or as advised by physicians.


  • Patients with known hypersensitivity to fexofenadine hydrochloride or to any ingredient of the drug.



  • Headache, drowsiness, dizziness.
  • Nausea.


  • Fatigue.

Not known:

  • Hypersensitivity reactions with manifestation such as angioedema, chest tightness, dyspnea, flushing and systemic anaphylaxis.
  • Insomnia, nervousness, sleep disorder or nightmares (paroniria).
  • Tachycardia, palpitations.
  • Diarrhoea.
  • Rash, urticarial, pruritus.


  • Although clinical experience generally has not revealed differences in responses between geriatric and younger patients to the drug, it should be considered that fexofenadine is substantially excreted by the kidneys and the risk of severe adverse reactions to the drug may be increased in patients with impaired renal function. Because geriatric patients may have decreased renal function, monitoring renal function may be useful and dosage should be selected with caution in these patients.
  • Although fexofenadine hydrochloride does not share the cardiotoxic potential of its parent drug terfenadine, fexofenadine has been associated with increased QTc interval syncope, and ventricular arrhythmia in at least one susceptible patient with preexisting cardiovascular risk.
  • Patients receiving preparations containing fexofenadine hydrochloride in fixed combination with pseudoephedrine hydrochloride should be instructed to take the drug only as prescribed and not to exceed the prescribed dosage. Patients also should be advised not to us other antihistamines or decongestants for self-medication. If nervourness, dizziness, or sleepiness occurs during therapy, patients should be advised to discontinue use of the fixed-combination preparation and consult a clinician.
  • Pregnancy: There are no adequate and controlled studies to date using fexofenadine in pregnant women, and fexofenadine hydrochloride should be using during pregnancy only when the potential benefits justify the possible risks to the fetus.
  • Lactation: Since there are no adequate and controlled studies to date on the use of fexofenadine during lactation in humans and because many drugs are excreted in human milk, fexofenadine should be used with caution in nursing women, and a decision should be made whether to discontinue nursing or the drug.
  • Patients may drive or perform task that require concentration while using fexofenadine. However, in order to identify sensitive people who have an unusual reaction to drugs, it is advisable to check the individual response before driving or performing complicated tasks.


Contact us

FACTORY 1: K63/1 Nguyen Thi Soc St., Xuan Thoi Dong, Hoc Mon, HCMC
Tel: +84 28 3718 2141 - Fax: +84 28 3718 2140

FACTORY 2: 40 Tu Do Avenue, VietNam-Singapore Industrial Park, Binh Duong
Tel: +84 274 376 7470 - Fax: +84 274 376 7469
Email : stada@stada.com.vn
Website: www.stada.com.vn

Visitors Counter